Status
Conditions
Treatments
About
Data will be gathered from patients who report having any kind of recurrent conjunctivitis and who, in accordance with clinical practice, are scheduled to have intravitreal injections, glaucoma surgery, cataract surgery, vitrectomy, combined cataract and vitrectomy, or corneal transplantation.
The data will be obtained using pseudonyms from the patients' medical records and will include the outcomes of swabs and surgeries performed in accordance with clinical practice for the patient's condition.
The following swabs will be taken into consideration for data analysis:
Four days before to surgery, a conjunctival swab is used to check for the presence and load of species that do not make up the typical conjunctival flora (Baseline-T0).
On the day of operation, a conjunctival swab is taken before to entering the recovery room (T1).
Following three minutes of 5% iodopovidone instillation in the eye to be operated on, a conjunctival swab (T2) was used.
Additionally, we will gather follow-up data from the medical record 24 and 30 hours after surgery (at day 34 +/- 7 days).
Full description
To determine if Zamidine® reduces ocular surface bacterial flora in surgical prophylaxis.
Secondary goals. To quantify and qualitatively evaluate ocular surface bacterial flora,
Data from patients' medical records will be pseudonymized and contain swabs and operation findings according to clinical practice for their condition.
Following swabs will be analyzed for data:
A conjunctival swab before operation day's recovery room (T1).
Follow-up data at 24 and 30 days after surgery (day 34 +- 7 days) will be collected from the medical record.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
56 participants in 1 patient group
Loading...
Central trial contact
Stanislao Rizzo, MD, Prof; Valentina Cestrone, Dr
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal